MCID: CYS014
MIFTS: 50

Cystadenocarcinoma

Categories: Cancer diseases, Endocrine diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Cystadenocarcinoma

MalaCards integrated aliases for Cystadenocarcinoma:

Name: Cystadenocarcinoma 11 53 43 14 16 71 75

Classifications:



External Ids:

Disease Ontology 11 DOID:3111
MeSH 43 D003536
NCIt 49 C2971
SNOMED-CT 68 21008007
UMLS 71 C0010631

Summaries for Cystadenocarcinoma

Disease Ontology: 11 An adenocarcinoma that derives from epithelial cells originating in glandular tissue, in which cystic accumulations of retained secretions are formed.

MalaCards based summary: Cystadenocarcinoma is related to mucinous cystadenocarcinoma and papillary cystadenocarcinoma. An important gene associated with Cystadenocarcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Innate Immune System and Disease. The drugs Etoposide and Lenograstim have been mentioned in the context of this disorder. Affiliated tissues include pancreas, ovary and lymph node, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased cell death in HCT116 cells

Wikipedia: 75 Cystadenocarcinoma is a malignant form of a cystadenoma and is a cancer derived from glandular... more...

Related Diseases for Cystadenocarcinoma

Diseases related to Cystadenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 662)
# Related Disease Score Top Affiliating Genes
1 mucinous cystadenocarcinoma 33.0 MUC16 MUC1 KRT7 CEACAM5 CEACAM3
2 papillary cystadenocarcinoma 33.0 TP53 MUC16 KRT7
3 pancreatic serous cystadenocarcinoma 32.9 KRT7 CEACAM5
4 appendix adenocarcinoma 32.8 TP53 KRT7 CEACAM5
5 serous cystadenocarcinoma 32.8 TP53 PTEN PGR MUC16 KRT7 BRCA1
6 bile duct cystadenocarcinoma 32.7 MUC1 KRT7 CEACAM5
7 ovarian cystadenocarcinoma 32.5 TP53 PTEN MUC16 MUC1 CEACAM5 BRCA1
8 ovarian serous cystadenocarcinoma 32.2 ZNF217 TP53 PTEN MUC16 MUC1 FBXW7
9 papillary serous adenocarcinoma 32.2 TP53 PGR KRT7 CEACAM5 BRCA1
10 cystadenoma 32.1 PTEN PGR MUC16 MUC1 KRT7 CEACAM5
11 mucinous adenocarcinoma 31.2 TP53 MUC1 KRT7 CEACAM5
12 papillary adenocarcinoma 31.0 TP53 MUC16 MUC1 KRT7 CEACAM5 BRCA1
13 pseudomyxoma peritonei 31.0 TP53 MUC2 MUC16 MUC1 KRT7 CEACAM5
14 benign teratoma 31.0 TP53 KRT7 CEACAM5
15 cystic teratoma 30.9 TP53 MUC1 KRT7 CEACAM5
16 obstructive jaundice 30.9 MUC16 KRT7 CEACAM5
17 ovarian cyst 30.8 PGR MUC16 MUC1 ESR2 CEACAM5 BRCA1
18 adenoma 30.7 TP53 MUC1 KRT7 BCL2 AKT1
19 pancreatic adenocarcinoma 30.7 VEGFA TP53 CDKN1A BCL2 AKT1
20 teratoma 30.7 VIM TP53 PTEN MUC1 KRT7 CEACAM5
21 appendiceal neoplasm 30.7 KRT7 CEACAM5
22 krukenberg carcinoma 30.7 KRT7 CEACAM5
23 mucoepidermoid carcinoma 30.7 VIM MUC2 MUC1 KRT7
24 adenocarcinoma 30.6 VEGFA TP53 PTEN MUC1 KRT7 CEACAM5
25 pleomorphic adenoma 30.6 VIM TP53 MUC1
26 ovarian cystadenoma 30.6 TP53 MUC16 KRT7 CEACAM5 BRCA1
27 mucinous ovarian cystadenoma 30.5 KRT7 CEACAM5
28 angiosarcoma 30.5 VIM VEGFA MUC1
29 breast ductal carcinoma 30.5 TP53 PTEN PGR MUC1 KRT7 ESR2
30 diffuse gastric cancer 30.4 TP53 PTEN BRCA1
31 endometriosis of ovary 30.4 PTEN PGR ESR2
32 klatskin's tumor 30.4 TP53 KRT7 CEACAM5
33 polycystic liver disease 1 with or without kidney cysts 30.4 MUC16 MUC1 KRT7 CEACAM5 CEACAM3
34 dysgerminoma 30.4 PTEN MUC1 KRT7 BRCA1
35 mixed cell type cancer 30.4 TP53 PTEN PGR KRT7 CEACAM5 BRCA1
36 cholangiocarcinoma 30.4 VEGFA TP53 PTEN MUC2 MUC1 KRT7
37 small cell carcinoma 30.4 TP53 PTEN KRT7 CEACAM5
38 adenosquamous carcinoma 30.4 PGR MUC1 KRT7 CEACAM5
39 testicular cancer 30.4 TP53 NANOG BRCA1 BCL2 AKT1
40 leiomyoma 30.3 VIM TP53 PGR ESR2 BCL2
41 intrahepatic cholangiocarcinoma 30.3 TP53 KRT7 CEACAM5 AKT1
42 salivary gland carcinoma 30.3 TP53 KRT7 CEACAM5
43 signet ring cell adenocarcinoma 30.3 TP53 MUC2 MUC1 KRT7 CEACAM5
44 carcinosarcoma 30.3 VIM TP53 PTEN PGR MUC1 KRT7
45 endometriosis 30.3 VEGFA TP53 PTEN PGR MUC16 ESR2
46 endosalpingiosis 30.3 TP53 KRT7 BRCA1
47 hemangioma 30.2 VIM VEGFA TP53 PTEN PGR MUC1
48 ductal carcinoma in situ 30.2 VEGFA TP53 PTEN PGR MUC1 ESR2
49 villous adenoma 30.2 TP53 KRT7 CEACAM5
50 breast fibroadenoma 30.2 TP53 PGR BRCA1

Graphical network of the top 20 diseases related to Cystadenocarcinoma:



Diseases related to Cystadenocarcinoma

Symptoms & Phenotypes for Cystadenocarcinoma

GenomeRNAi Phenotypes related to Cystadenocarcinoma according to GeneCards Suite gene sharing:

25 (show all 36)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.9 ABCB1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-106 9.9 BCL2
3 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.9 ZNF217
4 Increased shRNA abundance (Z-score > 2) GR00366-A-127 9.9 ABCB1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-131 9.9 ZNF217
6 Increased shRNA abundance (Z-score > 2) GR00366-A-134 9.9 BCL2
7 Increased shRNA abundance (Z-score > 2) GR00366-A-141 9.9 ABCB1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-147 9.9 ZNF217
9 Increased shRNA abundance (Z-score > 2) GR00366-A-148 9.9 ZNF217
10 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.9 PTEN
11 Increased shRNA abundance (Z-score > 2) GR00366-A-155 9.9 ZNF217
12 Increased shRNA abundance (Z-score > 2) GR00366-A-159 9.9 BCL2
13 Increased shRNA abundance (Z-score > 2) GR00366-A-16 9.9 PTEN
14 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.9 ZNF217
15 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.9 PTEN
16 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.9 BCL2
17 Increased shRNA abundance (Z-score > 2) GR00366-A-186 9.9 ZNF217
18 Increased shRNA abundance (Z-score > 2) GR00366-A-194 9.9 BCL2
19 Increased shRNA abundance (Z-score > 2) GR00366-A-199 9.9 ABCB1 BCL2
20 Increased shRNA abundance (Z-score > 2) GR00366-A-210 9.9 BCL2
21 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.9 PTEN
22 Increased shRNA abundance (Z-score > 2) GR00366-A-37 9.9 BCL2
23 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.9 PTEN
24 Increased shRNA abundance (Z-score > 2) GR00366-A-59 9.9 BCL2
25 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.9 PTEN
26 Increased shRNA abundance (Z-score > 2) GR00366-A-66 9.9 PTEN
27 Increased shRNA abundance (Z-score > 2) GR00366-A-68 9.9 BCL2
28 Increased shRNA abundance (Z-score > 2) GR00366-A-70 9.9 BCL2
29 Increased shRNA abundance (Z-score > 2) GR00366-A-77 9.9 BCL2
30 Increased shRNA abundance (Z-score > 2) GR00366-A-83 9.9 ZNF217
31 Increased shRNA abundance (Z-score > 2) GR00366-A-87 9.9 ABCB1 PTEN ZNF217
32 Increased shRNA abundance (Z-score > 2) GR00366-A-88 9.9 BCL2
33 Increased shRNA abundance (Z-score > 2) GR00366-A-93 9.9 PTEN
34 Increased shRNA abundance (Z-score > 2) GR00366-A-96 9.9 BCL2
35 Increased shRNA abundance (Z-score > 2) GR00366-A-99 9.9 ZNF217
36 Increased cell death in HCT116 cells GR00103-A-0 8.65 FBXW7

MGI Mouse Phenotypes related to Cystadenocarcinoma:

45 (show all 20)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.44 ABCB1 AKT1 BCL2 BRCA1 CDKN1A CEACAM5
2 neoplasm MP:0002006 10.4 AKT1 BCL2 BRCA1 CDKN1A CEACAM5 ESR2
3 endocrine/exocrine gland MP:0005379 10.34 ABCB1 AKT1 BCL2 BRCA1 CDKN1A CEACAM5
4 cellular MP:0005384 10.31 AKT1 BCL2 BRCA1 CDKN1A CEACAM5 ESR2
5 muscle MP:0005369 10.3 AKT1 BCL2 BRCA1 CDKN1A CEACAM5 ESR2
6 normal MP:0002873 10.28 AKT1 BRCA1 ESR2 FBXW7 MUC1 PGR
7 cardiovascular system MP:0005385 10.25 ABCB1 AKT1 BCL2 BRCA1 CDKN1A CEACAM5
8 digestive/alimentary MP:0005381 10.23 ABCB1 BCL2 BRCA1 CDKN1A CEACAM5 ESR2
9 embryo MP:0005380 10.22 AKT1 BCL2 BRCA1 CDKN1A FBXW7 NANOG
10 immune system MP:0005387 10.21 ABCB1 AKT1 BCL2 BRCA1 CDKN1A CEACAM5
11 liver/biliary system MP:0005370 10.2 ABCB1 AKT1 CDKN1A ESR2 FBXW7 MUC1
12 no phenotypic analysis MP:0003012 10.18 ABCB1 CDKN1A ESR2 MUC1 NANOG PGR
13 adipose tissue MP:0005375 10.18 AKT1 BCL2 BRCA1 CDKN1A CEACAM5 ESR2
14 renal/urinary system MP:0005367 10.17 BCL2 BRCA1 CDKN1A ESR2 KRT7 PTEN
15 limbs/digits/tail MP:0005371 10.08 BRCA1 CDKN1A ESR2 PGR PTEN TP53
16 reproductive system MP:0005389 10.07 ABCB1 AKT1 BCL2 BRCA1 CDKN1A ESR2
17 hematopoietic system MP:0005397 10 ABCB1 AKT1 BCL2 BRCA1 CDKN1A CEACAM5
18 respiratory system MP:0005388 9.97 AKT1 BRCA1 CDKN1A ESR2 FBXW7 PTEN
19 mortality/aging MP:0010768 9.86 ABCB1 AKT1 BCL2 BRCA1 CDKN1A CEACAM5
20 integument MP:0010771 9.36 AKT1 BCL2 BRCA1 CDKN1A ESR2 FBXW7

Drugs & Therapeutics for Cystadenocarcinoma

Drugs for Cystadenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 217)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Etoposide Approved Phase 2, Phase 3 33419-42-0 36462
2
Lenograstim Approved, Investigational Phase 3 135968-09-1
3
Everolimus Approved Phase 2, Phase 3 159351-69-6 70789204 6442177
4
Trastuzumab Approved, Investigational Phase 2, Phase 3 180288-69-1
5
Pertuzumab Approved Phase 2, Phase 3 380610-27-5
6
Gemcitabine Approved Phase 3 95058-81-4, 122111-03-9 60750
7
Cisplatin Approved Phase 3 15663-27-1 2767 5702198 441203
8
Paclitaxel Approved, Vet_approved Phase 2, Phase 3 33069-62-4 36314
9
Bevacizumab Approved, Investigational Phase 3 216974-75-3 135329020
10
Topotecan Approved, Investigational Phase 2, Phase 3 123948-87-8, 119413-54-6 60699 60700
11
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
12
Doxorubicin Approved, Investigational Phase 2, Phase 3 23214-92-8 31703
13
Metformin Approved Phase 2, Phase 3 1115-70-4, 657-24-9 4091
14
Olaparib Approved Phase 2, Phase 3 763113-22-0 23725625
15
Letrozole Approved, Investigational Phase 2, Phase 3 112809-51-5 3902
16
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 43805 11947679 6857599
17
Trametinib Approved Phase 2, Phase 3 871700-17-3 11707110
18
Dimethyl sulfoxide Approved, Vet_approved Phase 2, Phase 3 67-68-5 679
19
Sodium citrate Approved, Investigational Phase 2, Phase 3 68-04-2 23431961
20
Tamoxifen Approved Phase 2, Phase 3 10540-29-1, 54965-24-1 2733526
21
Atezolizumab Approved, Investigational Phase 2, Phase 3 1380723-44-3
22
Glutamic acid Approved, Nutraceutical Phase 3 56-86-0 33032
23
Citric acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 77-92-9 311
24
Camptothecin Experimental Phase 3 7689-03-4 24360
25
Edrecolomab Investigational Phase 3 156586-89-9
26
Oregovomab Investigational Phase 3 213327-37-8
27
Paclitaxel poliglumex Experimental, Investigational Phase 3 263351-82-2
28
Cediranib Investigational Phase 2, Phase 3 288383-20-0 9933475
29
Maleic acid Experimental, Investigational Phase 2, Phase 3 110-16-7, 110-17-8 444266 444972
30 Carotenoids Phase 3
31
Etoposide phosphate Phase 2, Phase 3 16760419
32 Adjuvants, Immunologic Phase 3
33 Formyltetrahydrofolates Phase 3
34 Tetrahydrofolates Phase 3
35 Albumin-Bound Paclitaxel Phase 2, Phase 3
36 Antimitotic Agents Phase 2, Phase 3
37 Tubulin Modulators Phase 2, Phase 3
38 Immunoglobulin G Phase 3
39 Protein Kinase Inhibitors Phase 2, Phase 3
40 Anti-Bacterial Agents Phase 2, Phase 3
41 Antibiotics, Antitubercular Phase 2, Phase 3
42 Liposomal doxorubicin Phase 2, Phase 3
43 Antineoplastic Agents, Hormonal Phase 2, Phase 3
44 Hormone Antagonists Phase 2, Phase 3
45 Hypoglycemic Agents Phase 2, Phase 3
46 Poly(ADP-ribose) Polymerase Inhibitors Phase 2, Phase 3
47 Estrogen Receptor Antagonists Phase 2, Phase 3
48 Estrogen Antagonists Phase 2, Phase 3
49 Aromatase Inhibitors Phase 2, Phase 3
50 Taxane Phase 3 108169

Interventional clinical trials:

(show top 50) (show all 223)
# Name Status NCT ID Phase Drugs
1 Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival? Unknown status NCT00719303 Phase 3
2 A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients With High Risk, Early Stage Endometrial Carcinoma Unknown status NCT00807768 Phase 3 Carboplatin;Paclitaxel
3 Randomized Phase II/III Trial to Assess the Efficacy of Platinum-based Chemotherapy vs Standard Non-platinum Therapy in Patients With Platinum-resistant Recurrent Ovarian Cancer (ROC) Unknown status NCT04055038 Phase 2, Phase 3 Platinum-Based Drug;Conventional chemotherapy
4 A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC # 704865) Followed by Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women With Newly Diagnosed, Previously Untreated, Stage III or IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
5 A Phase III Clinical Trial of Bevacizumab With IV Versus IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma Completed NCT00951496 Phase 3 Carboplatin;Cisplatin;Paclitaxel
6 CRAD001X2401: Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation Completed NCT03285802 Phase 2, Phase 3 Letrozole;Everolimus
7 Intergroup Randomized Phase III Study of Postoperative Irinotecan, 5-Fluorouracil and Leucovorin vs. Oxaliplatin, 5-Fluorouracil and Leucovorin vs. 5-Fluorouracil and Leucovorin for Patients With Stage II or III Rectal Cancer Receiving Either Preoperative Radiation and 5-Fluorouracil or Postoperative Radiation and 5-Fluorouracil Completed NCT00068692 Phase 3 Fluorouracil;Leucovorin Calcium;Oxaliplatin;Irinotecan
8 Phase III Randomized Study of Adjuvant Immunotherapy With Monoclonal Antibody 17-1A Versus No Adjuvant Therapy Following Resection for State II (Modified Astler-Coller B2) Adenocarcinoma of the Colon Completed NCT00002968 Phase 3
9 A Randomized Phase III Study of Tumor Volume Directed Pelvic Plus or Minus Para-Aortic Irradiation Followed by Cisplatin and Doxorubicin or Cisplatin, Doxorubicin and Paclitaxel for Advanced Endometrial Carcinoma Completed NCT00006011 Phase 3 Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
10 A Randomized Phase III Equivalence Trial of Irinotecan (CPT-11) Versus Oxaliplatin (OXAL)/5-Fluorouracil (5-FU)/Leucovorin (CF) in Patients With Advanced Colorectal Carcinoma Previously Treated With 5-FU Completed NCT00005036 Phase 3 irinotecan hydrochloride;oxaliplatin;leucovorin calcium;fluorouracil
11 Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer: a Randomized Phase III Trial (LEPRE Trial) Recruiting NCT05601700 Phase 3 Letrozole tablets;carboplatin AUC 5 and paclitaxel 175 mg/m2
12 A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum Recruiting NCT04095364 Phase 3 Carboplatin;Letrozole;Paclitaxel
13 Laparoscopic Cytoreduction After Neoadjuvant Chemotherapy Recruiting NCT04575935 Phase 3 Chemotherapy
14 A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-Oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma Recruiting NCT05256225 Phase 2, Phase 3 Carboplatin;Hyaluronidase-zzxf/Pertuzumab/Trastuzumab;Paclitaxel;Trastuzumab/Hyaluronidase-oysk
15 A Multicenter Phase 3, Double-Blind, Placebo-Controlled Study Comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin- Oregovomab) vs Chemotherapy (Paclitaxel-Carboplatin- Placebo) in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma Recruiting NCT04498117 Phase 3 Paclitaxel;Carboplatin
16 A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12, Monthly Cycles of Single Agent Paclitaxel or CT-2103 Versus No Treatment Until Documented Relapse in Women With Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy Active, not recruiting NCT00108745 Phase 3 Paclitaxel;Paclitaxel Poliglumex
17 A GCIG Intergroup Multicenter Phase III Trial of Open Label Carboplatin and Paclitaxel +/- NCI-Supplied Agent: Bevacizumab (NSC #704865) Compared With Oxaliplatin and Capecitabine +/- Bevacizumab as First Line Chemotherapy in Patients With Mucinous Epithelial Ovarian or Fallopian Tube Cancer (MEOC) Active, not recruiting NCT01081262 Phase 3 Capecitabine;Carboplatin;Oxaliplatin;Paclitaxel
18 A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865) Active, not recruiting NCT00565851 Phase 3 Carboplatin;Docetaxel;Gemcitabine Hydrochloride;Paclitaxel
19 GOG-0262: A Phase III Trial of Every-3-Weeks Paclitaxel Versus Dose Dense Weekly Paclitaxel in Combination With Carboplatin With or Without Concurrent and Consolidation Bevacizumab (NSC #704865) in the Treatment of Primary Stage II, III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer and ACRIN 6695: Perfusion CT Imaging to Evaluate Treatment Response in Patients Participating in GOG-0262 Active, not recruiting NCT01167712 Phase 3 Carboplatin;Paclitaxel
20 A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer Active, not recruiting NCT03914612 Phase 3 Carboplatin;Paclitaxel
21 A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer Active, not recruiting NCT02101788 Phase 2, Phase 3 Letrozole;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Tamoxifen Citrate;Topotecan;Trametinib Dimethyl Sulfoxide
22 A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer Active, not recruiting NCT02065687 Phase 2, Phase 3 Carboplatin;Metformin Hydrochloride;Paclitaxel
23 A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma Active, not recruiting NCT00942357 Phase 3 Carboplatin;Cisplatin;Paclitaxel
24 Short Course Adjuvant Vaginal Cuff Brachytherapy (VCB) in Early Endometrial Cancer Compared to Standard of Care (SAVE) Active, not recruiting NCT03422198 Phase 3
25 A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin Versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients With Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers Active, not recruiting NCT00217737 Phase 3 Fluorouracil;Leucovorin Calcium;Oxaliplatin
26 Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel Vs. Sandwich Therapy of Carboplatin and Paclitaxel Followed by Tumor Volume Directed Irradiation Then Further Carboplatin and Paclitaxel Active, not recruiting NCT02501954 Phase 3 Cisplatin;Carboplatin;Paclitaxel
27 A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS) Active, not recruiting NCT02502266 Phase 2, Phase 3 Cediranib;Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan;Topotecan Hydrochloride
28 A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer Active, not recruiting NCT02839707 Phase 2, Phase 3 Atezolizumab;Pegylated Liposomal Doxorubicin Hydrochloride
29 A Randomized, Double-Blinded, Placebo Controlled Phase III Trial Using Acetyl-L-Carnitine(ALC)(NSC# 747431) for the Prevention of Chemotherapy-Induced Peripheral Neuropathy in Patients With Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer Withdrawn NCT01492920 Phase 3
30 A Phase II Study of the Combination of Aflibercept (VEGF-Trap) Plus Modified FOLFOX 6 in Patients With Previously Untreated Metastatic Colorectal Cancer Unknown status NCT01652196 Phase 2 oxaliplatin;leucovorin;fluorouracil
31 A Clinical Study of Exploring Camrelizumab in the Treatment of Colorectal Mucinous Adenocarcinoma(MAC) Unknown status NCT04446091 Phase 1, Phase 2 Carilizumab + anti-angiogenic TKIs (available with fuquitinib, rigofenib, apatinib, etc.);Carilizumab + anti-angiogenic TKIs (available with fuquitinib, rigofenib, apatinib, etc.)+Irinotecan
32 A Phase II Study of Panitumumab in Combination With FOLFIRI After Progression on FOLFIRI Plus Bevacizumab in KRAS(Kirsten Rat Sarcoma) and NRAS Wild-Type Metastatic Colorectal Cancer. Unknown status NCT01814501 Phase 2 irinotecan hydrochloride;fluorouracil;leucovorin calcium
33 A Phase II Trial to Evaluate the Efficacy of Bortezomib and Pegylated Liposomal Doxorubicin in Patients With BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer Unknown status NCT03509246 Phase 2 Pegylated liposomal doxorubicin plus Bortezomib
34 A Phase II Trial of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) With Weekly Protein Bound Paclitaxel (Abraxane™) as Chemoimmunotherapy for Platinum-Refractory/Resistant Epithelial Ovarian, Primary Peritoneal and Fallopian Tube Cancer Completed NCT00466960 Phase 2 paclitaxel albumin-stabilized nanoparticle formulation
35 A Phase II Evaluation of a Urokinase-Derived Peptide (A6) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Completed NCT00939809 Phase 2
36 Phase II Study of Erlotinib Plus Carboplatin and Paclitaxel in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Completed NCT00059787 Phase 2 paclitaxel;carboplatin;erlotinib
37 A Phase II Evaluation of Belinostat (NSC #726630) and Carboplatin (NSC #241240) in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00993616 Phase 2 belinostat;carboplatin
38 A Phase 2 Trial of Letrozole and Everolimus in Relapsed Hormone Receptor Positive Ovarian, Fallopian Tube or Primary Peritoneal Carcinomas Completed NCT02283658 Phase 2 Everolimus;Letrozole
39 A Phase II Trial of Bevacizumab With Carboplatin and Weekly Paclitaxel as First-Line Treatment in Epithelial Ovarian, Primary Peritoneal, and Fallopian Tube Carcinoma Completed NCT01097746 Phase 2 Carboplatin;Paclitaxel
40 A Phase II Evaluation of Brivanib (BMS582664), an Oral, Multitargeted Growth Factor Tyrosine Kinase Inhibitor in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT00888173 Phase 2 Brivanib Alaninate
41 A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer Completed NCT00888615 Phase 2 Elesclomol Sodium;Paclitaxel
42 A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT01642082 Phase 2
43 A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT01225887 Phase 2 Nintedanib
44 A Phase II Evaluation of Pembrolizumab in Combination With IV Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT02853318 Phase 2 Cyclophosphamide
45 A Randomized Phase II Induction Discontinuation Trial of Emactuzumab Following Paclitaxel and Bevacizumab in Patients With Platinum-Resistant, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT02923739 Phase 2 Paclitaxel
46 A Phase II Evaluation of Temsirolimus (CCI-779) (NCI Supplied Agent: NSC# 683864,) in Combination With Carboplatin and Paclitaxel Followed by Temsirolimus Consolidation as First-Line Therapy in the Treatment of Clear Cell Carcinoma of the Ovary Completed NCT01196429 Phase 2 Carboplatin;Docetaxel;Paclitaxel;Temsirolimus
47 A Phase 2 Study of Sunitinib Malate in Recurrent or Metastatic Endometrial Carcinoma Completed NCT00478426 Phase 2 Sunitinib Malate
48 A Phase II Trial of AZD6244 (NSC# 748727) in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary or Peritoneum Completed NCT00551070 Phase 2 Selumetinib;Selumetinib Sulfate
49 Utility of Preoperative FDG-PET/CT Scanning Prior to Primary Chemoradiation Therapy to Detect Retroperitoneal Lymph Node Metastasis in Patients With Locoregionally Advanced Carcinoma of the Cervix (IB2, IIA ≥ 4 CM, IIB-IVA) or Endometrium (Grade 3 Endometrioid Endometrial Carcinoma; Serous Papillary Carcinoma, Clear Cell Carcinoma, or Carcinosarcoma (Any Grade); and Grade 1 OR 2 Endometrioid Endometrial Carcinoma With Cervical Stromal Involvement Overt in Clinical Examination or Confirmed by Endocervical Curettage Completed NCT00416455 Phase 1, Phase 2 ferumoxtran-10
50 A Phase II Evaluation of Copanlisib (BAY 80-6946), a Selective Inhibitor of PI3KCA, in Patients With Persistent or Recurrent Endometrial Carcinoma Harboring PIK3CA Hotspot Mutations Completed NCT02728258 Phase 2 Copanlisib

Search NIH Clinical Center for Cystadenocarcinoma

Cochrane evidence based reviews: cystadenocarcinoma

Genetic Tests for Cystadenocarcinoma

Anatomical Context for Cystadenocarcinoma

Organs/tissues related to Cystadenocarcinoma:

MalaCards : Pancreas, Ovary, Lymph Node, Liver, Breast, Colon, Salivary Gland

Publications for Cystadenocarcinoma

Articles related to Cystadenocarcinoma:

(show top 50) (show all 2437)
# Title Authors PMID Year
1
Role of cystic fluid in diagnosis of the pancreatic cystadenoma and cystadenocarcinoma. 53 62
18251127 2007
2
Improved early diagnosis of cystadenocarcinoma of the pancreas. 53 62
17287173 2007
3
Expression of MUC1 and MUC2 mucin antigens in intrahepatic bile duct tumors: its relationship with a new morphological classification of cholangiocarcinoma. 53 62
10573510 1999
4
Immunohistochemical demonstration of nonspecific cross-reacting antigen in normal and neoplastic human tissues using a monoclonal antibody. Comparison with carcinoembryonic antigen localization. 53 62
2187320 1990
5
Measurement of CA125, carcinoembryonic antigen, and alpha-fetoprotein in ovarian cyst fluid: diagnostic adjunct to cytology. 53 62
1696873 1990
6
Cystadenocarcinoma of the pancreas: neo-adjuvant therapy and CEA monitoring. 53 62
2296199 1990
7
Cystadenocarcinoma of the intrahepatic bile duct in a dog. 62
36198612 2022
8
Chronic expanding hematoma in the liver: a case report. 62
36414762 2022
9
Bioinformatics analysis of prognostic value and immunological role of MeCP2 in pan-cancer. 62
36323715 2022
10
Discovery of pathway-independent protein signatures associated with clinical outcome in human cancer cohorts. 62
36369472 2022
11
Cartilage oligomeric matrix protein acts as a molecular biomarker in multiple cancer types. 62
36255654 2022
12
High expression of the ANXA3 gene promotes immune infiltration and improves tumor prognosis in ovarian serous carcinoma using bioinformatics analyses. 62
36330402 2022
13
Urachal mucinous cystadenocarcinoma: A case report. 62
36280482 2022
14
Analysis of CXCL8 and its receptors CXCR1/CXCR2 at the mRNA level in neoplastic tissue, as well as in serum and peritoneal fluid in patients with ovarian cance. 62
35920183 2022
15
Low Grade Intraductal Carcinoma of Palate: An Extremely Rare Entity with Review of Literature. 62
36452681 2022
16
Hepatic Cysts: Reappraisal of the Classification, Terminology, Differential Diagnosis, and Clinicopathologic Characteristics in 258 Cases. 62
35778790 2022
17
Regulator of G Protein Signaling 20 Correlates with Long Intergenic Non-Coding RNA (lincRNAs) Harboring Oncogenic Potential and Is Markedly Upregulated in Hepatocellular Carcinoma. 62
36009801 2022
18
Pancancer Analysis of the Oncogenic and Prognostic Role of NOL7: A Potential Target for Carcinogenesis and Survival. 62
36077008 2022
19
A Rare Case of Low-Grade Serous Cystadenocarcinoma of the Ovary in a Seventeen-Year-Old Woman. 62
36128000 2022
20
A case of giant mucinous cystadenocarcinoma of the liver with intraoperative bleeding. 62
35637115 2022
21
Hexokinase 2 promoted cell motility and proliferation by activating Akt1/p-Akt1 in human ovarian cancer cells. 62
35953860 2022
22
Genome-Wide Identification and Validation of Gene Expression Biomarkers in the Diagnosis of Ovarian Serous Cystadenocarcinoma. 62
35954427 2022
23
[A Case Report of Psoas Abscess Formation Caused by Mucinous Cystadenocarcinoma]. 62
36046978 2022
24
A case of pancreatic mucinous cystadenocarcinoma with malignant ascites without recurrence for more than 8 years after surgery. 62
35546381 2022
25
Urachal Carcinoma, An Unusual Possibility of Hematuria; Case Report and Literature Review. 62
36010242 2022
26
Primary hepatic epithelioid angiomyolipoma: a small case series. 62
35578781 2022
27
Giant ovarian mucinous cystadenocarcinoma: A case report. 62
35846900 2022
28
[Mixed mucinous cystadenocarcinoma and columnar cell mucinous carcinoma of the breast with axillary lymph node metastases: report of a case]. 62
35673736 2022
29
Inferences of carboplatin response-related signature by integrating multiomics data in ovarian serous cystadenocarcinoma. 62
35285286 2022
30
Computed Tomography and Clinical Analysis of Ovarian Mucinous Tumors in Adolescent Patients. 62
34728347 2022
31
Expression Profiles of ID and E2A in Ovarian Cancer and Suppression of Ovarian Cancer by the E2A Isoform E47. 62
35740568 2022
32
The Cell Surface Heparan Sulfate Proteoglycan Syndecan-3 Promotes Ovarian Cancer Pathogenesis. 62
35628603 2022
33
Unexpected discovery of intrahepatic cholangiocarcinoma during follow-up in two cases of liver cysts: case report. 62
35571671 2022
34
Giant appendiceal mucocele as a first manifestation in a patient with silent ulcerative colitis: A case report. 62
35242261 2022
35
Pancreatic serous cystadenocarcinoma diagnosed with liver metastasis at 7 years after the resection of the primary serous neoplastic lesion. 62
35013932 2022
36
Giant Mucinous Cystadenocarcinoma of the Ovary with Cavitary Metastases to Lungs in a Postmenopausal Woman: A Rare Presentation. 62
35746916 2022
37
Cystadenocarcinoma of the mandible: An unusually aggressive presentation of this rare entity! 62
35183909 2022
38
Pan-cancer analysis identifies BIRC5 as a prognostic biomarker. 62
35331169 2022
39
Targetable IDH1 mutation identified in a rare case of pancreatic serous cystadenocarcinoma but not a series of serous cystadenomas. 62
35350224 2022
40
Liver metastasis mimicking a liver cyst of a thymoma in a 38-year-old immunocompromised patient. 62
34794195 2022
41
A pan-cancer analysis of the oncogenic role of secreted phosphoprotein 1 (SPP1) in human cancers. 62
35433956 2022
42
Primary Breast Mucinous Cystadenocarcinoma and Review of Literature. 62
35464581 2022
43
MRI is useful to suggest and exclude malignancy in mucinous cystic neoplasms of the pancreas. 62
34374801 2022
44
Mucinous cystadenocarcinoma of the breast: a new entity with broad differentials-a case report. 62
35224708 2022
45
Identification of bromodomain-containing proteins prognostic value and expression significance based on a genomic landscape analysis of ovarian serous cystadenocarcinoma. 62
36276071 2022
46
Cancer-specific survival and metastasis in pancreatic mucinous cystadenocarcinoma: A SEER-based cohort study. 62
36338678 2022
47
ANXA2P2: A Potential Immunological and Prognostic Signature in Ovarian Serous Cystadenocarcinoma via Pan-Carcinoma Synthesis. 62
35211410 2022
48
Immunohistochemical evaluation of forkhead box A1 and EphA5 markers in serous ovarian carcinomas, and their impact on the clinical outcome of patients. 62
36345952 2022
49
Sequential thermal ablation in combination with sclerotherapy using lauromacrogol as a successful translative therapy for an unresectable huge biliary cystadenocarcinoma: The first experience assisted by contrast-enhanced ultrasound. 62
35662112 2022
50
Papillary cystadenocarcinoma of the parotid gland: a rare sub-variant of salivary gland adenocarcinoma. 62
35252049 2022

Variations for Cystadenocarcinoma

Expression for Cystadenocarcinoma

Search GEO for disease gene expression data for Cystadenocarcinoma.

Pathways for Cystadenocarcinoma

Pathways related to Cystadenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 60)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.91 AKT1 BCL2 CDKN1A CEACAM3 FBXW7 MUC1
2
Show member pathways
13.79 VEGFA TP53 PTEN MUC16 MUC1 FBXW7
3
Show member pathways
13.79 VIM VEGFA TP53 PTEN MUC1 ESR2
4 13.7 ZNF217 VIM VEGFA TP53 PTEN PGR
5
Show member pathways
13.27 VIM VEGFA TP53 NANOG MUC1 CDKN1A
6
Show member pathways
12.91 VEGFA TP53 PTEN CDKN1A BCL2 AKT1
7
Show member pathways
12.86 AKT1 BCL2 BRCA1 CDKN1A PTEN TP53
8
Show member pathways
12.66 VEGFA TP53 PTEN CDKN1A BCL2 AKT1
9 12.63 VEGFA TP53 PTEN CDKN1A BRCA1 BCL2
10
Show member pathways
12.53 TP53 FBXW7 ESR2 CDKN1A BRCA1 BCL2
11
Show member pathways
12.45 TP53 PTEN BCL2 AKT1
12
Show member pathways
12.37 PGR FBXW7 CDKN1A BRCA1
13
Show member pathways
12.36 AKT1 BCL2 CDKN1A TP53
14 12.29 VEGFA PTEN BCL2 AKT1
15
Show member pathways
12.25 AKT1 CDKN1A PTEN TP53
16
Show member pathways
12.23 TP53 PTEN PGR ESR2 CDKN1A BRCA1
17
Show member pathways
12.19 AKT1 BCL2 CDKN1A PTEN TP53
18 12.18 VEGFA TP53 CDKN1A AKT1
19
Show member pathways
12.14 TP53 PTEN CDKN1A AKT1
20
Show member pathways
12.11 TP53 PTEN CDKN1A BRCA1 BCL2 AKT1
21
Show member pathways
12.1 AKT1 BRCA1 CDKN1A TP53
22 12.06 VEGFA PTEN BCL2 AKT1
23 12.04 TP53 PTEN CDKN1A BCL2
24 12.02 AKT1 BCL2 BRCA1 PTEN TP53 VEGFA
25 11.93 TP53 PTEN CDKN1A BCL2
26 11.91 TP53 PTEN CDKN1A BCL2
27 11.87 PTEN NANOG CDKN1A
28 11.87 VIM VEGFA ABCB1
29 11.84 TP53 PTEN AKT1
30 11.84 TP53 PTEN CDKN1A BCL2 AKT1
31 11.82 VEGFA PTEN AKT1
32
Show member pathways
11.81 TP53 CDKN1A BRCA1
33 11.77 TP53 CDKN1A AKT1
34 11.74 VIM CDKN1A AKT1
35 11.71 VEGFA TP53 BCL2 AKT1
36 11.7 VEGFA TP53 CDKN1A BCL2
37 11.69 PGR ESR2 BRCA1
38 11.69 VEGFA TP53 PTEN CDKN1A AKT1
39 11.68 VEGFA AKT1 ABCB1
40 11.66 CDKN1A BRCA1 BCL2
41
Show member pathways
11.63 TP53 PTEN AKT1
42 11.62 VEGFA CDKN1A AKT1
44 11.51 TP53 PTEN FBXW7 BRCA1 AKT1
45 11.48 TP53 CDKN1A BRCA1
46 11.43 VEGFA TP53 CDKN1A
47 11.37 PGR ESR2 AKT1
48 11.32 TP53 BRCA1 AKT1
49 11.3 TP53 CDKN1A BRCA1
50 11.29 VEGFA TP53 CDKN1A BRCA1 AKT1

GO Terms for Cystadenocarcinoma

Biological processes related to Cystadenocarcinoma according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 regulation of cell cycle GO:0051726 10.11 TP53 PTEN CDKN1A BRCA1 BCL2
2 cellular response to hypoxia GO:0071456 10.06 VEGFA TP53 PTEN BCL2
3 cellular response to ionizing radiation GO:0071479 9.91 TP53 CDKN1A BRCA1
4 negative regulation of gene expression GO:0010629 9.9 AKT1 CDKN1A FBXW7 PGR TP53 VEGFA
5 positive regulation of transcription from RNA polymerase II promoter in response to stress GO:0036003 9.84 TP53 MUC1
6 B cell lineage commitment GO:0002326 9.8 BCL2 TP53
7 negative regulation of reactive oxygen species metabolic process GO:2000378 9.8 TP53 BRCA1 BCL2
8 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.78 TP53 VEGFA
9 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.73 TP53 MUC1 CDKN1A
10 T cell lineage commitment GO:0002360 9.7 TP53 BCL2
11 signal transduction by p53 class mediator GO:0072331 9.58 TP53 CDKN1A
12 cellular response to decreased oxygen levels GO:0036294 9.54 AKT1 PTEN
13 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.43 TP53 MUC1 CDKN1A
14 negative regulation of cell growth GO:0030308 9.32 TP53 ESR2 CDKN1A BRCA1 BCL2

Molecular functions related to Cystadenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 10.16 VIM VEGFA TP53 PTEN PGR FBXW7
2 enzyme binding GO:0019899 9.73 AKT1 BRCA1 ESR2 PGR PTEN TP53
3 ubiquitin protein ligase binding GO:0031625 9.4 TP53 FBXW7 CDKN1A BRCA1 BCL2 ABCB1

Sources for Cystadenocarcinoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....